10 years of oral anticoagulant pharmacogenomics: what difference will it make? A critical appraisal (Q33517162)

27 July 2017

1 reference

title

10 years of oral anticoagulant pharmacogenomics: what difference will it make? A critical appraisal (English)

1 reference

27 July 2017

1 reference

1 reference

1 reference

Daniel Kurnik

1

1 reference

27 July 2017

Ronen Loebstein

2

1 reference

27 July 2017

Hillel Halkin

3

1 reference

27 July 2017

Eva Gak

4

1 reference

27 July 2017

Shlomo Almog

5

1 reference

27 July 2017

language of work or name

1 reference

1 December 2009

1 reference

27 July 2017

1 reference

27 July 2017

10

1 reference

27 July 2017

1955-1965

1 reference

27 July 2017

12

1 reference

Clopidogrel and the concept of high-risk pharmacokinetics.

27 July 2017

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.149

Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.149

Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.149

Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.149

Evaluating the impact of study-level factors on warfarin control in U.S.-based primary studies: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.149

Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.149

Estimation of the warfarin dose with clinical and pharmacogenetic data

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.149

The largest prospective warfarin-treated cohort supports genetic forecasting

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.149

Pharmacokinetics and pharmacodynamics of the enantiomers of warfarin in man

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.149

Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.149

Human P450 metabolism of warfarin

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.149

Pharmacogenetics of CYP2C9 and interindividual variability in anticoagulant response to warfarin

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.149

Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.149

Interindividual variability in sensitivity to warfarin--Nature or nurture?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.149

Clinical consequences of cytochrome P450 2C9 polymorphisms

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.149

Influence of CYP2C9 genotype on warfarin dose requirements--a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.149

Equal proportion of adult male and female homozygous for the 677C ? T mutation in the methylenetetrahydrofolate reductase polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.149

Influence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.149

In-vitro and in-vivo effects of the CYP2C9*11 polymorphism on warfarin metabolism and dose

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.149

CYP2C9*8 is prevalent among African-Americans: implications for pharmacogenetic dosing

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.149

CYP2C9 haplotype structure in European American warfarin patients and association with clinical outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.149

Upstream and coding region CYP2C9 polymorphisms: correlation with warfarin dose and metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.149

A genome-wide association study of acenocoumarol maintenance dosage.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.149

Pharmacogenetics of oral anticoagulants: a basis for dose individualization

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.149

Genotypes associated with reduced activity of VKORC1 and CYP2C9 and their modification of acenocoumarol anticoagulation during the initial treatment period

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.149

Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.149

Identification of the gene for vitamin K epoxide reductase

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.149

A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.149

Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.149

Regulatory polymorphism in vitamin K epoxide reductase complex subunit 1 (VKORC1) affects gene expression and warfarin dose requirement

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.149

VKORC1 polymorphisms, haplotypes and haplotype groups on warfarin dose among African-Americans and European-Americans

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.149

Genetic determinants of response to warfarin during initial anticoagulation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.149

Pharmacogenetics of warfarin: current status and future challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.149

A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.149

A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.149

CYP4F2 genetic variant alters required warfarin dose

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.149

CYP4F2 genetic variant (rs2108622) significantly contributes to warfarin dosing variability in the Italian population.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.149

CYP4F2 is a vitamin K1 oxidase: An explanation for altered warfarin dose in carriers of the V433M variant

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.149

Pharmacogenetic relevance of CYP4F2 V433M polymorphism on acenocoumarol therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.149

VKORC1 Asp36Tyr warfarin resistance marker is common in Ethiopian individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.149

Warfarin pharmacogenetics: CYP2C9 and VKORC1 genotypes predict different sensitivity and resistance frequencies in the Ashkenazi and Sephardi Jewish populations.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.149

Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.149

Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.149

Use of genetic and nongenetic factors in warfarin dosing algorithms

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.149

Predicting warfarin maintenance dose in patients with venous thromboembolism based on the response to a standardized warfarin initiation nomogram.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.149

Genetic-based dosing in orthopedic patients beginning warfarin therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.149

Combination of phenotype assessments and CYP2C9-VKORC1 polymorphisms in the determination of warfarin dose requirements in heavily medicated patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.149

Relative contribution of CYP2C9 and VKORC1 genotypes and early INR response to the prediction of warfarin sensitivity during initiation of therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.149

Laboratory and clinical outcomes of pharmacogenetic vs. clinical protocols for warfarin initiation in orthopedic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.149

Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.149

Should we be applying warfarin pharmacogenetics to clinical practice? No, not now.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.149

Evidence for a pharmacogenetic adapted dose of oral anticoagulant in routine medical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.149

CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.149

Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.149

Delivery of optimized anticoagulant therapy: consensus statement from the Anticoagulation Forum

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.149

21 January 2018

Identifiers

DOI

10.2217/PGS.09.149

1 reference

27 July 2017

1 reference